PROVENGE Designed to stimulate a patient's own immune system

PROVENGE - Designed to stimulate a patient's own immune system

Written by Jack Leeroy
Chicago, IL. -- Apr 21, 2007 -- /prbuzz/ -- PROVENGE is an investigational product that may represent the first in a new class of active cellular immuno

therapies that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

The FDA has to give their opinion on whether they will or will not approve the drug provenge on May 15th. If the FDA issue an approval letter, then the company Dendreon would have to provide additional data to the FDA on 2010.

WARNING: Investing in a drug that the FDA has not approve is Gambling. Gambling can cost you all of your money.

PR BUZZ - PROVENGE